Synonyms: TJ 003234 | TJ003234 | TJM2
Compound class:
Antibody
Comment: Plonmarlimab (TJM2/TJ003234) is a humanized IgG1 monoclonal antibody that is designed to neutralise granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF2) cytokine activity. It was developed by I-Mab Biopharma for potential to treat autoimmune diseases, and is likely to be Hu23F4-27 as claimed in I-Mab patent WO2018050111A1 [2].
COVID-19: Plonmarlimab is being evaluated as a mechanism to down-regulate elevated inflammation/cytokine release syndrome in patients with COVID-19 [1] in a Phase 2/3 study. |
Classification | |
Compound class | Antibody |
International Nonproprietary Names | |
INN number | INN |
11595 | plonmarlimab |
Synonyms |
TJ 003234 | TJ003234 | TJM2 |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 1140 |
Other databases | |
GtoPdb PubChem SID | 442878670 |
Search PubMed clinical trials | plonmarlimab |
Search PubMed titles | plonmarlimab |
Search PubMed titles/abstracts | plonmarlimab |